Skip to main content

Table 1 Hazard ratios for disease-free survival of breast cancer

From: The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

 

All patients ( N  = 303)

Event ( N  = 87)

Crude HR (95% CI)

P

Adjusted HRa(95% CI)

P

 

N

%

N

%

F/U duration (median), days

67-1930 (1540)

67-1930 (1161)

    

Age, mean (SD)

46.6 (10.7)

46.5 (11.4)

0.99 (0.79-1.23)

0.897

1.00 (0.98-1.02)

0.911

  < 39

81

26.7

25

28.7

1.00

 

1.00

 

  40-49

108

35.6

29

33.3

0.85 (0.50-1.46)

0.557

1.21 (0.68-2.16)

0.525

  50 ≤

114

37.7

33

37.9

0.83 (0.49-1.41)

0.496

0.97 (0.54-1.76)

0.926

Menopausal statusb

        

  Premenopausal

191

63.3

54

62.1

1.00

 

1.00

 

  Postmenopausal

111

36.8

33

37.9

1.02 (0.66-1.58)

0.915

1.01 (0.62-1.64)

0.982

BMI, mean (SD)

23.3 (3.17)

23.5 (3.39)

    

  < 25 kg/m2

229

75.6

62

71.3

1.00

 

1.00

 

  ≥ 25 kg/m2

74

24.4

25

28.7

1.11 (0.70-1.77)

0.665

1.10 (0.66-1.81)

0.723

TNM stage

        

  I

115

38

18

20.7

1.00

 

1.00

 

  IIA -IIB

123

40.5

36

41.4

1.89 (1.06-3.37)

0.031

1.46 (0.78-2.73)

0.242

  IIIA -IIIC

65

21.5

33

37.9

3.97 (2.20-7.13)

<.0001

4.41 (2.27-8.57)

<.0001

Tumor size

        

  < 2 cm

159

52.5

26

29.9

1.00

 

1.00

 

  ≥ 2 cm

144

47.5

61

70.1

2.78 (1.74-4.44)

<.0001

2.42 (1.46-4.02) c

<.0001

Lymph node status

        

  Negative

170

56.1

40

46

1.00

 

1.00

 

  Positive

133

43.9

47

54

1.54 (1.27-1.86)

<.0001

1.47 (0.93-2.31) d

0.092

Histologic gradeb

        

  I-II

160

55.4

32

39

1.00

 

1.00

 

  III

129

44.6

50

61

2.11 (1.35-3.30)

0.001

1.36 (0.81-2.28)

0.248

Nuclear gradeb

        

  I-II

145

54.6

33

39.8

1.00

 

1.00

 

  III

133

45.4

50

60.2

1.96 (1.26-3.06)

0.003

1.16 (0.70-1.95)

0.564

ER status

        

  Positive

173

57.1

36

41.4

1.00

 

1.00

 

  Negative

130

42.9

51

58.6

2.40 (1.56-3.70)

<.0001

2.34 (1.46-3.75)

<.0001

PR status

        

  Positive

159

52.5

33

37.9

1.00

 

1.00

 

  Negative

144

47.5

54

62.1

2.19 (1.41-3,.39)

0.001

1.45 (0.79-2.65)

0.235

Adjuvant chemotherapyb

       

  Yes

216

72.7

74

87.1

1.00

 

1.00

 

  No

81

27.3

11

12.9

0.34 (0.17-0.65)

0.001

0.61 (0.26-1.41)

0.249

Radiation therapyb

        

  Yes

184

61.7

49

57.7

1.00

 

1.00

 

  No

114

38.3

36

42.4

1.26 (0.81-1.94)

0.310

2.08 (1.24-3.49)

0.006

Hormone receptor therapyb

       

  Yes

198

66.2

41

47.7

1.00

 

1.00

 

  No

101

33.8

45

52.3

2.65 (1.73-4.06)

<.0001

2.03 (0.90-4.60)

0.089

  1. a Adjusted for BMI (< 25 and ≥25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (yes and no).
  2. b Due to missing information, total frequency is less than 303.
  3. c Adjusted for BMI (< 25 and ≥25 kg/m2), lymph node status (yes and no), ER status (positive and negative) and radiation therapy (yes and no).
  4. d Adjusted for BMI (< 25 and ≥25 kg/m2), tumor size (< 2 and ≥2 cm2), ER status (positive and negative) and radiation therapy (yes and no).
  5. HR, hazard ratio; CI, confidence interval; BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us